News stories about Vericel Corporation (NASDAQ:VCEL) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vericel Corporation earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 47.5760955170109 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Vericel Corporation (NASDAQ:VCEL) opened at $4.25 on Friday. The company has a current ratio of 2.50, a quick ratio of 2.22 and a debt-to-equity ratio of 0.44. Vericel Corporation has a twelve month low of $2.25 and a twelve month high of $6.30.
Vericel Corporation (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Vericel Corporation had a negative net margin of 45.11% and a negative return on equity of 265.45%. The firm had revenue of $14.26 million during the quarter. research analysts forecast that Vericel Corporation will post -0.6 earnings per share for the current fiscal year.
Vericel Corporation Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
What are top analysts saying about Vericel Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vericel Corporation and related companies.